Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for the treatment of endometrial cancer. The effect of lapatinib on tumour cell growth and receptor activation was studied in a panel of human endometrial cancer cell lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Konecny, G E, Venkatesan, N, Yang, G, Dering, J, Ginther, C, Finn, R, Rahmeh, M, Fejzo, M Schoenberg, Toft, D, Jiang, S-W, Slamon, D J, Podratz, K C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275492/
https://www.ncbi.nlm.nih.gov/pubmed/18334972
http://dx.doi.org/10.1038/sj.bjc.6604278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275492/
https://www.ncbi.nlm.nih.gov/pubmed/18334972
http://dx.doi.org/10.1038/sj.bjc.6604278

Ejemplares similares